SEEL - Seelos Therapeutics, Inc.
Chart Events
Triple Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.0600 |
| Open | 1.0800 |
| Bid | 1.0600 x 900 |
| Ask | 1.0700 x 800 |
| Day's Range | 1.0200 - 1.1000 |
| 52 Week Range | 0.4200 - 2.2500 |
| Volume | 671,037 |
| Avg. Volume | 1,590,087 |
| Market Cap | 45.849M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7730 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
Fair Value
Related Research
- PR Newswire
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the initiation of a preclinical study of SLS-007 in Parkinson's disease (PD) delivered through an adeno associated viral (AAV) vector targeting the non-amyloid component core (NACore) of alpha synuclein (α-synuclein).
- GlobeNewswire
Seelos Therapeutics Announces Final Data from Phase I PK/PD Study of Intranasal Racemic Ketamine (SLS-002) and Clinical Development Plans
NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced final safety data from its Phase I pharmacokinetics/pharmacodynamics (PK/PD) Study of Intranasal Racemic Ketamine (SLS-002) as well as the planned design of a double blind, placebo-controlled Proof of Concept (PoC) study for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD) to begin in the fall of 2020. Seelos is planning to initiate this PoC study in two parts: Part A is an open-label study of 16 patients, and will be followed by Part B which is a double blind, placebo-controlled study of approximately 120 patients.
- Simply Wall St.
Seelos Therapeutics, Inc. (NASDAQ:SEEL): When Will It Breakeven?
Seelos Therapeutics, Inc.'s (NASDAQ:SEEL): Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company...
- GlobeNewswire
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to provide updates regarding data from the Phase I study of SLS-002 on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time. Seelos will also provide an overview of the design for Seelos’ next study of SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD) during the call. The call will feature a discussion with Michael E. Thase, MD, professor of psychiatry at the University of Pittsburgh Medical Center and the Western Psychiatric Institute and Clinic.
- Insider Monkey
Hedge Funds Warming Up To Seelos Therapeutics, Inc. (SEEL)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- GlobeNewswire
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the initiation of a preclinical study of SLS-004 in Parkinson’s disease (PD) through an all-in-one lentiviral vector targeting the synuclein alpha (SNCA) gene. Seelos is constructing a bimodular viral system harboring an endogenous alpha-synuclein (α-synuclein) transgene and inducible regulated repressive CRISPR/Cas9-unit to achieve constitutive activation and inducible suppression of PD-related pathologies.
- GlobeNewswire
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Seelos Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims.
NEW YORK, May 19, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Seelos Therapeutics,.
- GlobeNewswire
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to discuss the unmet medical needs in suicide and depression on Tuesday, May 26, 2020 at 1:00 p.m. Eastern Time. The call will feature a discussion with Distinguished University Health Professor Emeritus at the University of South Florida College of Medicine, David V. Sheehan, MD, MBA. Dr. Sheehan will discuss the unmet medical needs in treating suicidal patients with depression and other mental health conditions.
- GlobeNewswire
Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference
NEW YORK, May 18, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.
- GlobeNewswire
Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Judith Dunn, Ph.D. to its Board of Directors. Dr. Dunn has had an extensive career in the pharmaceutical and biotechnology industries having served in various roles at F. Hoffman-La Roche AG from March 2010 through January 2018, including Vice President, Global Head of Clinical Development and Principal Medical Group Leader, Neuroscience.
- GlobeNewswire
Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
NEW YORK, May 15, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.
- GlobeNewswire
Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
NEW YORK, May 12, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.
- GlobeNewswire
Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005)
NEW YORK, May 04, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.
- GlobeNewswire
Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome
NEW YORK, April 30, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.
- GlobeNewswire
Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provides its first quarter business update and pipeline developments. While the COVID-19 outbreak is reaching unprecedented pandemic levels globally, Seelos empathizes with those experiencing the devastating loss of life and the transformation of their daily lives. Seelos is on the frontline of mental health research and is progressing on schedule with its clinical development of SLS-002 in Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).
- GlobeNewswire
Seelos Therapeutics Announces Additional Interim Data from Phase I Studies of Intranasal Racemic Ketamine (SLS-002)
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced additional interim data from its Phase I studies of Intranasal Racemic Ketamine (SLS-002). Seelos also announced that it completed its Type C meeting with the U.S. Food and Drug Administration (FDA) as scheduled to discuss the protocol design for a study of SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).
- GlobeNewswire
Seelos Therapeutics Announces Closing of Public Offering of Common Stock
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share. The net proceeds to Seelos from this offering are expected to be approximately $3.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Seelos. Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates.
- GlobeNewswire
Seelos Therapeutics Announces Pricing of $4.5 Million Public Offering of Common Stock
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 1,125,000 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.
- GlobeNewswire
Seelos Therapeutics Announces Proposed Public Offering of Common Stock
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has commenced a proposed underwritten public offering of shares of common stock. In addition, the Company intends to grant the underwriters an option to purchase up to an additional 15% of the aggregate number of shares of common stock sold in the offering on the same terms and conditions to cover over-allotments, if any. All of the shares of common stock in the offering will be sold by Seelos.
- GlobeNewswire
Seelos Therapeutics Announces European Medicines Agency Guidance to Design an Open-Label Pivotal Study for SLS-005 in Sanfilippo Syndrome
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has received a written response from the European Medicines Agency (EMA), in lieu of a face to face meeting, offering guidance for Seelos’ planned European study of SLS-005 (IV trehalose) in patients with mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome. Based upon the written response from the EMA, Seelos will design an open-label, non-placebo controlled, Phase IIb/III pivotal study for the treatment of patients with Sanfilippo syndrome types A and B in the European Union (EU).
- GlobeNewswire
Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007
NEW YORK, March 06, 2020 -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous.
- GlobeNewswire
Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March
Cowen 40th Annual Health Care Conference on March 2nd-4th in Boston, MARoth Capital 32nd Annual Conference on March 16th-17th in Laguna Niguel, CA NEW YORK, Feb. 19, 2020 --.
- Simply Wall St.
Raj Mehra Is The Founder of Seelos Therapeutics, Inc. (NASDAQ:SEEL) And They Just Spent US$100k On Shares
Even if it's not a huge purchase, we think it was good to see that Raj Mehra, the Founder of Seelos Therapeutics, Inc...
- GlobeNewswire
Seelos Therapeutics Announces Pricing of $5 Million Public Offering of Common Stock
Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the pricing of an underwritten public offering of 6,666,667 shares of its common stock, at a price to the public of $0.75 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 999,999 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.
- Simply Wall St.
Did You Manage To Avoid Seelos Therapeutics's (NASDAQ:SEEL) Devastating 73% Share Price Drop?
Seelos Therapeutics, Inc. (NASDAQ:SEEL) shareholders should be happy to see the share price up 26% in the last...
